Last updated on December 2019

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Brief description of study

B7451015 is a Phase 3 study to evaluate PF-04965842 with or without Topical Medications in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis and have completed a qualifying Phase 3 study. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated over approximately two years of study participation. Patients who meet safety step-down criteria will have their dose reduced once, from 200 mg QD to 100 mg QD, or from 100 mg QD to placebo.

Clinical Study Identifier: NCT03422822

Find a site near you

Start Over

Matsuyama Dermatology Clinic

Nakano-ku, Japan
  Connect »

Tokyo Medical University Hospital

Shinjyuku-ku, Japan
  Connect »

Iidabashi Skin Clinic

Chiyoda-ku, Japan
  Connect »

Fukuwa Clinic

Chuo-ku, Japan
  Connect »